Biopact is a Molecular Rebar Design Company focusing on nanoscale biomaterials company developing the MGMR intracellular delivery vehicle. MGMR is a cellular-engineering tool for biomanufacturing and agricultural processes which value efficient delivery of RNAs, peptides, and genetic materials.
MGMR is a highly-efficient intracellular delivery vehicle, consisting of a stabile dispersion of hollow, nanoscale tubules approximately 1/10,000th the width of a human hair. The high aspect-ratio, nanoscale profile of MGMR allows it to readily penetrate cells without compromising membrane integrity or inducing cytotoxicity. Its high surface-to-volume ratio and tunable surface chemistry allow it to readily transport both small and large-molecular payloads into the cytoplasm, including growth factors, oligonucleotides, proteins and gene-editing complexes.
Biopact has evaluated the cytotoxicity profile of MGMR across multiple cell-lines and investigated safety and efficacy in murine biodistribution and clearance models. Our in vivo studies demonstrate that MGMR is biologically-inert, well-tolerated and rapidly cleared from non-targeted tissues. In a murine therapeutic model, MGMR loaded with doxorubicin (Dox) demonstrated a remarkable capability to rapidly concentrate drug in targeted tissues and extend half-life of its molecular cargo.
Promising assessments of intracellular delivery performance in different eukaryotic cell-types suggest the potential for developing MGMR as a biomolecular delivery vehicle for various expression platforms and cell-factories of interest to agricultural and industrial applications, including mammalian cell-lines, yeasts, bacteria and plants. Robust cellular uptake observed with MGMR offers the potential to deliver molecular payloads to difficult-to-penetrate cell-types or those acutely sensitive to detergents and other conventional methods for transmembrane delivery.
|
|
|
|
|
1-10 employees
View all BioPact employees
|
|
|
Biotechnology Research
|
|
|
12310 Trail Driver Street, Austin, Texas 78737, US
|
|
|
2014
|
|
|
Drug Delivery, Nanotechnology, Rnai, Genetic Engineering, Gene Delivery, Protein Delivery, Agricultural Bioengineering, Antibody Delivery, Cellular Delivery, Genetically Modified Organisms, Intracellular Delivery, Strain Development, Trans-Membrane Delivery
|
Kent Phelps is the CEO of BioPact. To contact Kent Phelps email at [email protected] or [email protected]. Or you may call +18005617087, +14804679000 or 800-674-3582
Find accurate personal emails, work emails and phone numbers for employees
Accelerate prospecting with instant access to 350M professionals from 40M companies with the right contact details.